Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$9.80 USD
+0.65 (7.05%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $9.79 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Earnings News For LRMR
-
Larimar: Q1 Earnings Snapshot
-
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
-
Larimar: Q4 Earnings Snapshot
-
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
-
Larimar: Q3 Earnings Snapshot
-
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
-
Larimar: Q2 Earnings Snapshot
-
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
-
Larimar: Q1 Earnings Snapshot
-
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial?s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich?s Ataxia and First Quarter 2023 Financial Results
-
Larimar: Q4 Earnings Snapshot
-
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
-
Larimar: Q3 Earnings Snapshot
-
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
-
Larimar: Q2 Earnings Snapshot
-
Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results